ArticleMediators of inflammation2012
IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.
Article in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Peripheral Blood and Cerebrospinal Fluid Cytokine Levels in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis.Frontiers in neuroscience · 2019Pooled it
- Multimodal MRI links gray matter volume loss and temporal lobe susceptibility to CSF immunological profiles in Guillain-Barré syndrome.Frontiers in immunology · 2026Article
- IL-22, a vital cytokine in autoimmune diseases.Clinical and experimental immunology · 2024Review
- Genetically predicted N-Acetyl-L-Alanine mediates the association between CD3 on activated and secreting Tregs and Guillain-Barre syndrome.Frontiers in neuroscience · 2024Article
- Extensive cytokine biomarker analysis in serum of Guillain-Barré syndrome patients.Scientific reports · 2023Article
- IL-22 inhibits bleomycin-induced pulmonary fibrosis in association with inhibition of IL-17A in mice.Arthritis research & therapy · 2022Article
- Expression analysis of cytokine transcripts in inflammatory demyelinating polyradiculoneuropathy.Metabolic brain disease · 2021Article
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- Clinical and biochemical profile of Guillain Barré Syndrome in Pakistan.Neurosciences (Riyadh, Saudi Arabia) · 2021Article
- Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammation markers in patients with papilledema due to idiopathic intracranial hypertension.Indian journal of ophthalmology · 2021Article
- A review of the role of genetic factors in Guillain-Barré syndrome.Journal of molecular neuroscience : MN · 2021Review
- Altered serum levels of IL-36 cytokines (IL-36α, IL-36β, IL-36γ, and IL-36Ra) and their potential roles in Guillain-Barré syndrome.Medicine · 2020Article
- Guillain Barré syndrome and COVID-19: Possible role of the cytokine storm.Autoimmunity reviews · 2020Article
- Cerebrospinal fluid dynamics modulation by diet and cytokines in rats.Fluids and barriers of the CNS · 2020Article
- Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction.Theranostics · 2020Article
- The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System.Frontiers in aging neuroscience · 2020Review
- Interleukin-22 Polymorphisms inMediators of inflammation · 2020Article
- Th17 cells and their cytokines serve as potential therapeutic target in experimental autoimmune neuritis.Brain and behavior · 2019Article
- Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.Frontiers in immunology · 2019Article
- Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is an acute autoimmune-mediated inflammatory demyelinating disease that causes rapidly progressing paralysis and occasionally respiratory failure. We hypothesized that interleukin (IL)-17 and IL-22 are elevated in GBS and participate in the autoimmune inflammatory response of GBS. We used sandwich enzyme-linked immunosorbent assay (ELISA) to measure the IL-17 and IL-22 levels in the CSF, and plasma from 22 GBS patients at the acute phase and 18 healthy controls (HC). The results show that CSF and plasma levels of IL-17 and IL-22 are elevated in GBS patients compared with HC. IL-17 and IL-22 levels in CSF, respectively, are correlated with GBS disability scale scores (GDSs). Meanwhile, IL-17 and IL-22 levels in CSF, IL-22 in CSF, and plasma of GBS patients have positive correlation, respectively. The increased levels of IL-17 and IL-22 in CSF may be explained by the disruption of blood-brain barrier (BBB) and peripheral nervous system (PNS) local inflammation in GBS. Meanwhile, the elevated levels of these two cytokines in plasma suggest the activation of Th17 and Th22 cells in the systemic immune response of GBS. Our data provide preliminary evidence that GBS is associated with high levels of IL-17 and IL-22 in CSF and plasma. These cytokines display pathogenic potential and may serve as useful biomarkers for GBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.